Short Interest in Assembly Biosciences Inc (ASMB) Drops By 41.0%
Assembly Biosciences Inc (NASDAQ:ASMB) saw a significant decline in short interest in April. As of April 30th, there was short interest totalling 1,406,200 shares, a decline of 41.0% from the April 15th total of 2,385,411 shares. Based on an average daily volume of 444,710 shares, the days-to-cover ratio is presently 3.2 days. Currently, 6.2% of the shares of the company are sold short.
Several equities analysts have recently weighed in on the company. BidaskClub cut Assembly Biosciences from a “hold” rating to a “sell” rating in a research report on Wednesday, May 22nd. William Blair reiterated an “outperform” rating on shares of Assembly Biosciences in a research report on Friday, May 10th. Chardan Capital reiterated a “hold” rating and issued a $30.00 price target on shares of Assembly Biosciences in a research report on Monday, April 15th. Finally, Zacks Investment Research upgraded Assembly Biosciences from a “hold” rating to a “buy” rating and set a $24.00 price target for the company in a research report on Thursday, February 21st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. Assembly Biosciences presently has a consensus rating of “Buy” and an average target price of $43.00.
Assembly Biosciences stock opened at $15.61 on Monday. Assembly Biosciences has a 52 week low of $13.13 and a 52 week high of $48.91. The company has a debt-to-equity ratio of 0.06, a current ratio of 7.97 and a quick ratio of 7.97. The stock has a market cap of $398.84 million, a P/E ratio of -3.92 and a beta of 1.60.
Institutional investors have recently bought and sold shares of the stock. Tibra Equities Europe Ltd purchased a new position in Assembly Biosciences during the first quarter worth about $918,000. New York State Common Retirement Fund grew its position in Assembly Biosciences by 15.3% during the fourth quarter. New York State Common Retirement Fund now owns 23,300 shares of the biopharmaceutical company’s stock worth $527,000 after buying an additional 3,100 shares in the last quarter. Victory Capital Management Inc. grew its position in Assembly Biosciences by 3.4% during the fourth quarter. Victory Capital Management Inc. now owns 530,909 shares of the biopharmaceutical company’s stock worth $12,009,000 after buying an additional 17,669 shares in the last quarter. Emerald Mutual Fund Advisers Trust grew its position in Assembly Biosciences by 13.3% during the first quarter. Emerald Mutual Fund Advisers Trust now owns 418,143 shares of the biopharmaceutical company’s stock worth $8,233,000 after buying an additional 49,230 shares in the last quarter. Finally, Deutsche Bank AG grew its position in Assembly Biosciences by 29.8% during the fourth quarter. Deutsche Bank AG now owns 54,606 shares of the biopharmaceutical company’s stock worth $1,234,000 after buying an additional 12,525 shares in the last quarter. Institutional investors and hedge funds own 86.61% of the company’s stock.
About Assembly Biosciences
Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.
See Also: Futures Contract
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.